1.
|
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111827, GEN416, NCT00802737
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OMB110911, NCT00748189
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110913, NCT00824265
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-CD20-001, NCT00092274
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-CD20-402, NCT00093314
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111773, Hx-CD20-406, NCT00349349
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111775, Hx-CD20-409, The MUNIN trial, NCT00494780
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111776, GEN415, NCT00622388
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110921, NCT00811733
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110927, NCT00823719
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0283, NCT01002755
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112758, NCT01077622
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C18083/2048, 2009-016725-34, NCT01108341
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI CLL 11, NCT01113632
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CLL0809, NCT01244451
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 115991, NCT01520922
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: OMB111148, NCT00742144
|
|
18.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112855, NCT01110031
|
|
19.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1109-CA, PCI-32765, NCT01217749
|
Mobile | Español
